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During the last ten years, transcatheter aortic valve implantation (TAVI) has become a
reliable and valid alternative treatment for elderly patients with severe symptomatic aortic
valve stenosis requiring valve replacement and being at high or intermediate surgical
risk. While common femoral arteries are the access site of choice in the vast majority of
TAVI patients, in up to 15–20% of TAVI candidates this route might be precluded due
to the presence of diffuse atherosclerotic disease, tortuosity or small vessel diameter.
Therefore, in order to achieve an antegrade or retrograde implant, several alterative
access routes have been described, namely trans-axillary, trans-aortic, trans-apical,
trans-carotid, trans-septal, and trans-caval. The aim of this paper is to give a concise
overview on vascular access sites for TAVI, with a particular focus on patient’s selection
criteria, imaging, technical aspects, and clinical outcome.
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INTRODUCTION
Transcatheter aortic valve implantation (TAVI) has gained prime time as the preferred treatment
for elderly patients suffering from severe symptomatic aortic valve stenosis and at high or
intermediate risk for standard surgery (1). During the last decade, cardiac centers have faced a
continuously increasing number of TAVI procedures that overtook, in some countries, the number
of standard surgical aortic valve replacements (2).
Experience acquired in this setting suggests that procedural success is achieved through an
accurate pre-procedural evaluation, a perfect matching between commercially available prostheses
and the peculiar anatomical characteristics of TAVI patients, technical implant skills of the TAVI
team and a tailored choice of access options, the latter representing one of the most critical points.
The trans-femoral access represents the preferred route in the vast majority of TAVI patients
because of its minimal invasiveness and the possibility to perform the procedure under conscious
sedation without intubation. Increased expertise and technical advancements lead to a significant
reduction of major access site-related vascular complications that occur, nowadays, in <10% of
cases.
Due to its wide diffusion and feasibility, the trans-femoral access is the preferred route in the
majority of the clinical trials and is recommended as first choice by all guidelines and consensus
documents (1–5).
Nonetheless, data from randomized clinical trials (3–7) and registries (8–14) clearly show
that the trans-femoral access might be precluded in up to 25–30% of TAVI patients due to the
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presence of severe arterial disease (Figure 1). In particular,
obstructive peripheral vascular disease, femoro-iliac tortuosity,
aortic atheromas, or the presence of previously implanted arterial
grafts can seriously limit the possibility of a transfemoral access
(Figure 2).
Beside technical aspects, the choice of the access in TAVI
seems to be independently associated with an impact on
prognosis, in particular in the case of the trans-apical approach,
when manipulation of the left ventricular apex is needed (14, 15).
This evidence highlights the priority of an appropriate access
route selection in TAVI. So far, several alternative options for
antegrade or retrograde TAVI procedures have been described,
namely the trans-femoral, trans-axyllarian, trans-aortic, trans-
apical, trans-carotid, trans-septal, and trans-caval. Nonetheless,
no randomized comparisons are so far available, thus the choice
is often based on data derived from retrospective analyses of
national registries as well as on local experience.
In this report we give a concise overview on accesses for TAVI,
with a particular focus on patient’s selection criteria, technical
aspects and clinical outcome.
FEMORAL ACCESS
The common femoral artery represents the preferred access in
the vast majority of TAVI procedures. This route allows a fully-
percutaneous TAVI under conscious sedation/local anesthesia.
Careful procedural planning and accurate choice of the proper
site for vascular puncture are keys for procedural success.
Patient’s Selection and Planning
While obtaining the femoral access is technically easy, planning
a successful procedure through this route might be demanding
and time consuming. Unplanned (or angio-only guided) femoral
access should be avoided whenever possible, this representing
a potential risk of severe vascular complications. A detailed
reconstruction of the arterial route along with precise aortic
annular dimensions can be obtained at CT scan analysis, adding
invaluable data about the feasibility of different approaches.
As a standard protocol in our center, patients referred for
TAVR undergo an angio CT-scan and a 3D reconstruction
extending from the aortic annulus to the superficial femoral
artery with commercially available software packages (e.g.,
3mensio structural Heart, Pie Medical Imaging, Maastricht, The
Netherlands). The relationship of the vessels, in particular of the
bifurcation, with the femoral head should be carefully evaluated.
In selected cases, the angiographic reconstruction will help to
perform a fluoro-guided puncture of the artery with no or
minimal contrast injection (Figure 3).
While analyzing the common femoral and iliac arteries,
particular attention should be paid to their caliber (that has to
exceed at least 5.5mm, ideally 6.5mm for a 18F delivery system)
and to the presence and extension of atherosclerotic plaques,
calcifications as well as to the degree and extension of tortuosity.
When calcifications are concentric, located anywhere from the
aorto iliac bifurcation to the femoral bifurcation, even in the
presence of vessels of good caliber, this could represent a potential
contraindication for the trans-femoral access and the need for
alternative accesses should be discussed within the Heart Team.
A good estimation of the caliber of the iliac artery is of paramount
importance in balloon size selection when transient occlusion is
needed in bailout situations.
Beside detailed analysis of the iliiac-femoral arteries, a
cautious exploration of the aorta should be performed as well
in order to identify potential challenges such as tortuosity,
presence of aneurysms, thrombotic appositions, or aortic arch
calcifications. All these anatomic features are potential sources of
embolization or causes of vascular rupture/dissection when large
catheters are inserted and, therefore, can be considered as relative
contraindications for a transfemoral approach.
Technical Aspects
When deemed suitable for transcutaneous access, an optimal
puncture site is then identified (Figures 3A,B) in the segment
of the common femoral artery extending between the inferior
epigastric artery and the distal portion of the common femoral
artery, ideally 1 cm above the femoral bifurcation (Figure 3C). In
case of vascular complications, the most common being failure
of the vascular closure device; having enough distance from the
femoral bifurcation will allow the placement of a covered stent or,
in alternative, a safe surgical isolation and repair.
In presence of an anterior calcification of the femoral
artery, attention should be paid when percutaneous suture-
based vascular closure devices (e.g., Perclose, Prostar, both from
Abbot medical) are meant to be used, because their efficacy
might be reduced. In those cases, surgical cut down with or
without surgical endarterectomy or alternative access, should be
considered.
When performing a transcutaneous femoral artery puncture
for TAVR, we almost invariably try to roadmap the route. For
this purpose a selective angiography with a pigtail inserted
by the contralateral access through a cross-over technique is
used (Figures 4A–C). Then, the needle is directed toward the
middle of the pigtail, and the arterial wall is punctured on
its anterior aspect (Figure 4D). This will minimize the risk of
vascular injury and enhance the success rate of percutaneous
closure devices as well. While in the first TAVI series the
Prostar was widely adopted, nowadays vascular preclosure with
two Perclose/Proglide (Abbot Medical) devices inserted on
the medial (2 o’clock) and lateral (11 o’clock) aspect of the
arterial wall are used in the vast majority of transfemoral
cases. When using this technique, attention should be paid
in removing the contralateral pigtail before the insertion of
the closure devices in order to prevent the entrapment of the
catheter, a complication requireing surgical removal (Figure 4E).
In some centers, omolateral injections using micropuncture
needles (3F) are used to identify the optimal site. In obese
patients with deep femoral arteries (i.e., >8 cm from the
skin) as well as in cases with anterior calcifications, surgical
cut down or alternative accesses should be considered. At
case completion, when doubting about the efficacy of the
preclosure devices implanted, a good tip to keep in mind is
to perform a crossover from the contralateral femoral artery
before removing the main sheath. This will allow to position
a safety wire in the iliac/femoral artery that could be used
rapidly for balloon occlusion and, eventually, to deliver a covered
stent.
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FIGURE 1 | Bar plot reporting rates of transfemoral implants as compared to alternative accesses in national registries.
FIGURE 2 | Three dimensional angio CT reconstruction obtained with the 3mensio software in a patient with severe aortic stenosis referred for TAVI (A). Snake view of
the aorta and right iliacofemoral arteries (B) clearly shows diffuse calcific atherosclerotic disease precluding trans-femoral route. (C) shows diffuse tortuosity of the iliac
arteries, while (D) the incidental finding of an infrarenal abdominal aneurysm. All the above mentioned findings might preclude a transfemoral approach.
Outcome Data
Increased awareness of operators regarding the intrinsic
difficulties of the femoral access in TAVI associated with
technological advancements such as the progressive reduction of
the caliber of the vascular sheaths and delivery systems has led
to a perceivable reduction in the occurrence of major vascular
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FIGURE 3 | Three dimensional reconstruction of the arterial system (A) and cross section of the common right femoral artery at the optimal puncture site (B). The
artery shows a good caliber (exceeding 6.5mm as evident from the yellow circle) and no calcifications. Moderate tortuosity of the superficial iliac artery is evident at
both 3 D and angio reconstruction (C). In particular, the angio reconstruction allows for the fluoro guided detection of the optimal access site, based on its relationship
with the femoral head.
FIGURE 4 | Step by step approach for the transfemoral access. Once the common femoral artery has been deemed suitable for a trans-femoral approach due to the
good caliber and the lack of anterior calcifications, the relationships with the femoral head (inferior border of the femoral head is highlighted in red), observed at the
angio reconstruction, have to be described (A). Through a contralateral crossover, the pigtail is inserted in the common right femoral artery (B) and its position
confirmed by contrast injection (C). Vessel puncture aiming at the anterior aspect of the femoral artery is then performed (D). Particular attention has to be paid in
removing the pigtail before inserting the suture based closure devices with the consequent risk of catheter jailing and need for surgical removal (E).
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complications, declined from above 10% in early PARTNER
trials to about 6% in the more recent SURTAVI, NOTION and
COREVALVE high risk trials (3–7). These data are in line with
real-life data reported from national registries [(8–14), Table 1].
TRANS-AXILLARY/TRANS-SUBCLAVIAN
ACCESS
The subclavian artery is the terminal branch of the
brachiocephalic artery. For the purpose of a retrograde TAVI
implant, the right axillary/subclavian artery is rarely (if not ever)
used due to the anatomy of the vessel leading to an unfavorable
implantation angle. The left subclavian artery arises as the third
branch of the aortic arch after the left common carotid artery,
and exits the thorax from the superior thoracic aperture between
the anterior and middle scalene muscles before passing between
the first rib and the clavicle. At the lateral border of the first rib it
continues as the axillary artery. The proximal third of the axillary
artery (i.e., between the lateral border of the first rib and the
medial border of the pectoralis minor) represents the ideal target
for both surgical and percutaneous approaches (Figures 5A,B).
Patient’s Selection and Planning
Trans-axillary approach represents a valid option in 5–10% of
patients referred for transarterial retrograde TAVI (32) and,
in many centers, is considered the second option when trans-
femoral TAVI is not feasible. Currently available software for
CT-scan analysis allows a semi-automated 3D reconstruction of
the axillary and subclavian arteries. As for the femoral approach,
caliber (>6.5mm), calcifications, tortuosity and anatomical
relationships with side branches have to be taken into account.
Particular attention should be paid to the aortic take-off of the
subclavian artery, a typical site of atherosclerotic calcific plaque
apposition.
Worth to mention is the different histological structure of the
axillary and subclavian arteries when compared to the femoral
artery. In fact, the subclavian, and axillary arteries are of the
elastic type while the femoral is of the muscular type with a media
containing smooth muscle cells instead of elastic fibers and a
thicker, and more fibrous, adventitia (33). Those characteristics
predispose this access to vascular complications such as ruptures
or dissections. For these reasons, in the presence of a patent right
internal mammarian artery to left anterior descending artery, the
use of this access has been questioned due to the increased risk of
vascular complication leading to the potentially lethal acute graft
occlusion.
Technical Aspects
Transaxillarian approach was usually performed through a
surgical cut down (Figure 5C), but the feasibility of a full
percutaneous approach has been demonstrated (33).
When performing a surgical cut down, a 6–7 cm incision 1 cm
below and parallel to the clavicle from the mid clavicular line to
the axillary line is performed. Then, the pectoralis major muscle
is dissected along its fibers, the pectoralis minor is retracted,
and vessels are exposed. Attention is required to not damage to
the nervous structures of the brachial plexus. Once isolated, a
single or double purse string suture is placed on the subclavian
artery and access to lumen is achieved by means of a direct
puncture. In selected cases, a 10–12 cm Dacron vascular graft
can be anastomosed end-to-side to the subclavian artery with
and a standard large femoral sheath (>18F), custom modified by
cutting the distal portion in order to allow to accommodate the
sheath inside the vascular graft without extending its distal edge
into the subclavian artery (34) (Figures 5D,E). This modified
technique avoids extensive manipulation of the artery in case of
borderline vascular diameter allowing a safe implantation even
in patients with patent left internal mammary artery to the left
anterior descending coronary artery.
A fully percutaneuos approach was described by Schäfer
et al. in 2012 as the “Hamburg Sankt Georg Approach” (33).
The axillary artery was landmarked with a regular J-wire and
punctured below the clavicula to allow manual compression and
reduce the risk of pneumothorax. Subsequently, the procedure
was carried out as for the trans-femoral access. In their report,
vascular complications significantly decreased when two Proglide
(Abbott Vascular Devices) were used instead of a ProStar (Abbott
TABLE 1 | Procedural outcomes according to the access site.










1.4–6.7% (30 days stroke)
2.3–4.1% (1 year stroke)
3.4–34.1
5.9–20.1
Trans-axyllarian (16) 97.9 5.7% 7.8% life threatening
36.2% major bleeding
2.1% 24.7
Trans-Aortic (17–24) 87–100 6.1–13% 0.3–12% 0–3.2% 0–14
Trans-Apical (13, 25–28) 90–96 4.6–14% 3.6–6.1% 1.3–4.1% 5.4–11.0
Trans-Carotid (29) 100 6.3% 4.2% 3.1% (all TIAs, stroke not
reported)
26.5
Trans-Caval (30, 31) 100 8% 12%
(6% transcaval related)
5% 16
‡Data derived from Partner A, Partner B, Partner II, Notion and SURTAVI trials.
†Data derived from TVT, Gary, UK TAVI, Observant and France2 registries.
Frontiers in Cardiovascular Medicine | www.frontiersin.org 5 July 2018 | Volume 5 | Article 88
Biasco et al. Choosing the Right Access for the Right Patient
FIGURE 5 | Anatomy of the subclavian and axillary artery (A) and its relationship with the clavicle, the first rib and the medial border of the pectoralis minor. The first
segment of the axillary artery (comprised between the two red lines) is usually the target for both surgical or percutaneous approaches. (B) shows the angiographic
anatomy of the subclavian and axillary artery. (C) reports the surgical cut down for axillary artery with the vessel isolated by two yellow rubber bands. (D) shows a
“Chimney approach” performed by means of a 15 cm × 8mm GelwaveTM prosthesis, a gelatin sealed woven polyester peripheral vascular graft and a Check-FloVR
PerformerTM 18F Cook sheath (length 35 cm), routinely used for the transfemoral modified by cutting the distal portion in order to obtain an approximate length of
10–12 cm that could allow to accommodate the sheath inside the vascular graft without extending its distal edge into the axillary artery. (E) shows the navigation of a
Medtronic Corevalve delivery system through the left subclavian artery.
Vascular Devices, Redwood City, California). At completion of
the case, closure of the axillary artery was achieved with the pre-
implanted vascular closure devices, while a peripheral balloon
was always advanced in the subclavian artery to control possible
bleedings.
Self-expandable prostheses are chosen in the vast majority
of cases performed through this access, mainly the Medtronic
Corevalve, while balloon expandable devices have been used only
in selected cases.
Outcome Data
Trans-axillary approach has shown to be non-inferior to the
femoral approach in terms of procedural and medium-term
results in a propensity matched comparison derived from the
Italian national registry (16). Both groups showed comparable
rates of procedural success (subclavian 97.9 vs. femoral 96.5%,
p = ns), major vascular complications (5.0 vs. 7.8%, p = ns)
and life-threatening bleeding (7.8 vs. 5.7%, p = ns). Freedom
from cardiovascular death as well as survival at 2 years was also
comparable between the two groups, providing strong support to
the use of this approach as a valid alternative to the trans-femoral
access.
DIRECT TRANSAORTIC ACCESS
The direct transaortic TAVI has been originally reported by Bapat
in 2012 (17, 18). The new concept behind this first report was
the use of the short transapical TAVI delivery system for the
retrograde TAVI implant through the ascending aorta. Since its
advent, the trans-aortic technique was well accepted by heart
teams and it has become a valid option in case of severe
vascular disease impeding trans-femoral TAVI (19–24). Both
balloon-expandable and self-expandable prostheses are currently
used with good results. Some dedicated delivery systems are
commercially avaliable, but standard trans-femoral systems can
be used, adopting some tricks in room set-up (long delivery
systems requiring good support).
Patient’s Selection and Planning
Most of the patients selected for TAVI are in fact eligible
for a direct trans-aortic access with few exclusions, basically
represented by the presence of thorax deformities, very short
ascending aorta, porcelain aorta and the presence of a patent
venous coronary artery bypass graft with proximal anastomosis
on the ascending aorta at risk of damage. When facing a severely
atherosclerotic aortic arch (with a good ascending portion),
the direct aortic access might represent a good choice. This
will allow to avoid extensive manipulation of an atherosclerotic
aortic arch with the consequent risk of hembolization. In case a
trans-aortic TAVI is planned, a careful evaluation of the quality
of the aortic wall area where the purse string sutures will be
placed (free of calcium for at least 1 square cm) is mandatory
(Figures 6A,B). This is usually performed at CT-scan analysis,
and for this purpose, a native contrast-free scan can be enough.
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FIGURE 6 | (A) shows a 3D reconstruction of the left ventricle, aortic valve and ascending aorta in a patient with severe aortic stenosis. Lack of anterior calcifications
of the aortic walls allowed for a transaortic approach. (B) shows an a case of a patients with extensive anterior aortic calcifications, a potential contra-indication for
trans-aortic puncture. (C) the distance between the aortic entry site and the aortic valve annulus is of paramount importance for the valve release. A minimal distance
of 6 cm is required for small delivery systems. The larger the valve size, the longer will be the length for delivery system retrieval.
Then, the trajectory between the entry site and the aortic valve
annulus has to be considered in order to allow a perfect alignment
between the delivery system and the native aortic valve. An
“horizontal” ascending aorta (i.e., with an angle >70◦) requires
more banding of the delivery system with the subsequent risk of
valve malalignment. Additionally, in order to allow the complete
release of the valve, the aortic entry should be at least 6 cm
between the above the aortic annulus (Figure 6C).
Technical Aspects
The right antero-lateral mini-thoracotomy at second intercostal
space and the direct trans-aortic TAVI through an upper
mini-sternotomy requires a different set-up of the cath lab
as compared to the traditional trans-femoral access. First, the
fluoroscopy arm is placed at patient’s left side with cardiac
surgeon and cardiologist standing together at the patient’s right
side. Compared to the mini-sternotomy, the advantage of the
right mini-thoracotomy is represented by a lateral entry site into
aortic lumen (right side) allowing for a straight trajectory of the
delivery system through the stenotic aortic, with a consequent
reduced risk of aortic damage.
Trans-aortic TAVI can be successfully performed with the
Edwards Sapien balloon-expandable valve, using the dedicated
trans-apical delivery system (valve mounted with the tissue
skirt toward the tip of the delivery system) as well as with
the Corevalve system (19–24). Other devices such as the trans-
femoral Boston Lotus, the trans-femoral Accurate Neo Symetis
and the St Jude Portico valve systems have been rarely used by
the trans-apical route.
Due to the invasiveness of the approach, procedures
are invariably performed under general anesthesia and the
mechanical ventilation is obtained with a single or a double
lumen endotracheal tube.
In the case the right antero-lateral mini-thoracotomy is
choosen, a 5–8 cm long incision is usually performed at the right
second intercostal space, parallel to the right clavicle, andmuscles
are gently dissected. If possible, mammary vessels should not
be damaged. The pleural space is opened and the lung is either
deflated (with a double-lumen tube) or displaced in order to
identify the pericardium at the level of the ascending aorta. Ribs
are retracted, the pericardium is opened and stay sutures are
placed to expand the surgical field and pull the ascending aorta
toward the operators. To identify the entry site, the ascending
aorta is gently manipulated for calcium detection or a Doppler
probe is used for the same purpose. The distance between the
entry site and the aortic annulus is confirmed with a graduated
pigtail catheter placed against the non-coronary aortic cusps
under fluoroscopy. Two 3-0 or 4-0 polypropylene purse-string
sutures reinforced by pledgets are placed at the entry site on the
lateral wall of the ascending aorta. The ascending aorta is then
punctured within the purse-string sutures and a soft guidewire is
advanced toward the aortic valve, allowing for a standard valve
implant. In case the trans-aortic TAVI is performed through
an upper mini-sternotomy, the incision (5–8 cm) is carried out
along themid line of the thorax and the upper part of the sternum
is sawed to reach the cranial portion of the ascending aorta. Once
a sternal spreader is in place and the pericardium is opened,
placement of the purse string sutures follows the same rules of
the mini-thoracotomy but entry site is at a more more anterior.
The advantage of an upper mini-sternotomy is that pleural spaces
are not open. Full sternotomy is usually performed in high-
risk patients requiring combined procedures such as off-pump
coronary artery bypass grafting and/or tricuspid valve repair on
cardiopulmonary bypass and beating heart can be considered in
selected cases (35–37). The device insertion is similar to the upper
mini-sternotomy.
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FIGURE 7 | Procedural steps in trans-apical approach. (A) surgical incision at
the left fifth intercostal space and, after placement of a rib retractor and
opening pericardium the apex is exposed. (B) Purse-string sutures reinforced
by pledgets are placed at the apex and stabilized with a Tourniquet. (C) after
apex is punctured within the purse-string sutures and a soft guidewire is
advanced with an antegrade approach toward the aortic valve and positioned
in the ascending aorta. Then, a conventional 18F sheath is advanced in the left
ventricular cavity.
Clinical Results
While trans-apical can be at risk of apical bleeding and major
access related complications in frail elderly patients (38, 39), the
transaortic TAVI can be a valid alternative in preventing apical
manipulations and peripheral vascular injuries, with satisfactory
clinical results. Procedural success rates of above 90% have
been reported in the vast majority of series, with a 30 days
mortality ranging from 6.1 to 13%. In a recently published review
comparing trans-aortic vs. trans-apical TAVI procedures, Dunne
et al. (40) reported similar 30-day outcomes: mortality of 7.9%
(TAO) and 9.7% (TA); procedural success of 95% for both; rate of
conversion to surgical aortic valve replacement of 2.1% (TAO)
and 1.1% (TA); rate of new pacemaker implantation of 5.5%
(TAO) and 5.9% (TA). A trend toward a lower rate of stroke in
the trans-aortic TAVI group was also evident (0.9% in TAO vs
2.1% in TA).
Compared to the transapical TAVI, avoidance of apical
incision with the relatedmyocardial scar reduces the risk of apical
aneurysm formation, ventricular rupture and late arrhythmias
(35).
TRANSAPICAL ACCESS
The transapical access represents the historical alternative to the
trans-femoral TAVI and can be performed in all patients with
contraindications to the transfemoral TAVI (13, 25–28).
Patient’s Selection and Planning
The approach requires a left mini-thoracotomy andgeneral
anesthesia. Contraindications to the transapical access route are
a few, basically represented by a severely reduced left ventricular
function and the presence of apical thrombus. Preoperative CT-
scan images, can be useful in identifying the ventricular apex
and its relationship with the thorax wall while transthoracic
echocardiogram right before the procedure helps in identifying
the apex and guiding the mini-thoracotomy. With regards
to the commercially available transcatheter aortic valves and
delivery systems, the transapical TAVI requires short dedicated
delivery catheters. So far only the Edwards Sapien balloon-
expandable valve and the self-expandable Symetis valve provide
such possibility.
Technical Aspects
A left antero-lateral mini-thoracotomy at the fifth intercostal
space requires a different set-up of the cath lab as compared to
the trans-femoral and the transaortic accesses. The fluoroscopy
arm is placed at patient’s right side with cardiac surgeon and
cardiologist standing together at the patient’s left side. Due to the
invasiveness of the approach, the transapical TAVI is performed
under general anesthesia and the mechanical ventilation is
obtained with a single lumen endotracheal tube. A 5–8 cm long
incision is performed at left fifth intercostal space andmuscles are
gently dissected (Figure 7A). The pleura space is opened. After
the placement of a rib retractor the pericardium is opened and
stay sutures are placed to expand the surgical field and pull apex
toward the operators. Two concentric 3-0 or 4-0 polypropylene
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purse-string sutures reinforced by pledgets are placed at the
apex (Figure 7B). Then, the apex is punctured within the purse-
string sutures and a soft guidewire is advanced toward the aortic
valve and the ascending aorta (Figure 7C). The valve is placed
and delivered following standard techniques. Once implant is
achieved, the delivery system and the sheath are gently removed
and sutures are secured. In order to lower the intraventricular
pressure during this phase, a short period of rapid pacing can be
useful.
Clinical Results
The transapical TAVI can be an alternative to the transfemoral
TAVI in case of severe vascular disease. Also in this case, reported
procedural success rate are above 90% with 30 days mortality rate
ranging from 4 to 14%.
According to data derived from the German GARY registry,
trans-apical access is an independent predictor of 1 yearmortality
in TAVI patients. While this effect is related to the impact of
apical manipulation or associated to the increased co-morbidities
of those patients is still widely debated (14, 15).
OTHER ACCESSES
Starting from the original description of the first in human
case of a percutaneous transcatheter implantation of an aortic
valve prosthesis performed by Alain Cribier in April 2002 (41),
access’s choice seems to represent an intrinsic challenge of
this technique. In their ground-breaking report, the procedure
was performed through an antegrade approach from the right
femoral vein. Access to the left atrium was obtained by trans-
septal puncture, then the stenotic aortic valve was crossed on
an antegrade fashion creating a venous arterial loop to allow
the advancement and the stability of the percutaneous valve.
Apart from this pioneering description, the antegrade transeptal
approach is nowadays not considered as an option in patients
unsuitable for other conventional accesses.
Rarely, the trans-carotid approach can be considered as an
alternative option in patients unsuitable for trans-femoral, trans-
subclavian or surgical trans-aortic/apical approaches.
While pro’s are represented by avoidance of chest opening and
the possibility to perform the procedure under local anesthesia,
cons are mainly related to the necessity of a complex pre
procedural planning with carotid and vertebral doppler to
exclude significant atheromatosis, and cerebral MRI to confirm
patency of the circle of Willis that could limit the cerebral
perfusion during the carotid occlusion. While both common
carotid arteries can be chosen, usually the left one is preferred
given the straight pathway to the aortic valve. From a practical
perspective, a 2 cm incision above the left clavicle allows the
surgical exposure of the common carotid artery. Attention to
avoid injury to the vagus nerve has to be paid. The arterial
lumen is then accessed by direct puncture and surgical closure
is performed at case completion. To the best of our knowledge,
percutaneous access was not reported in this setting due to
the complex management of potential bleedings and vascular
damage. Mylotte et al. reported the feasibility and the safety of
this trans-carotid approach in 96 patients enrolled in 3 different
French sites (42). In their series, no major bleedings nor vascular
complications related to the access site occurred, while only three
transient ischemic attacks and no strokes were reported. No
direct or propensity matched comparisons to trans-femoral TAVI
are available so far.
The trans-caval approach, described by Greenbaum et al.
in 2014 (29) is considered as the last resort in patients not
qualifying for any other vascular access. Procedural planning
requires a baseline CT-scan to identify a calcium free target
on the right abdominal aortic wall allowing for a safe passage
from the inferior vena cava to the aortic lumen of the large
bore sheath. After having obtained a femoral venous access, the
inferior vena cava is punctured by means of a stiff CTO wire
(usually a Confianza PRO 12) mounted over a microcatheter
and a standard RCA or IMA guiding catheter. The caval and
aortic walls are perforated by using electrocautery applied at
the distal end of the wire. Once obtained access to the aortic
lumen, the wire is snared and both the microcatheter and
the guiding catether are advanced into the abdominal aorta.
This allows for the placement of a stiff “0.035” wire and the
advancement of a large introducer sheath from the femoral vein
into the aortic lumen for conventional retrograde aortic valve
replacement. At case completion, heparin is reversed, and the
aortic perforation is closed using a conventional vascular, duct
or ventricular septal defect occluder device. The authors recently
reported the 30-day outcomes of the first 100 patients from the
prospective multicentre study (30). Device success, defined as
successful trans-caval access and deployment of a closure device
without death or emergent surgery was obtained in 98% of cases.
Nonetheless, VARC-2 major or life threatening bleedings were
evident in 12 patients, retroperitoneal hematomas were found
at post procedural CT-scans in 24% of patients, while in 8 cases
implant of an aortic covered stent was deemed necessary during
the index procedure or in the early post procedural phase. Thus,
so far, based on the above mentioned data, this approach should
be considered as a proof of concept rather than as an effective
alternative option to standard TAVI access routes and should
only be considered in patients without alternative treatment
options.
CONCLUSIONS
Retrograde trans-femoral TAVI is the access of choice in the
vast majority of patients with severe aortic stenosis deemed at
intermediate or high operative risk for traditional surgical aortic
valve replacement, and current guidelines highlight that the
feasibility of a transfemoral approach should be considered as a
determinant aspect favoring TAVI in the decisionmaking process
when choosing between percutaneous or surgical procedures.
In line with current recommendations, also in our clinical
experience, the transfemoral access is always considered as the
first option. Nonetheless, in a discrete percentage of cases, this
access might be precluded. This implies that several different
options have been proposed as alternatives, each of them with
unique features, pros and cons. The availability of different,
mainly surgical accesses, should be seen as a possibility for
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the patients to be treated with a trans-catheter approach and
for the involved heart team as a concrete opportunity to
increase even more the collaboration between cardiac experts
with interventional or surgical skills. So far, no randomized
head to head comparisons between different access options
are available, and if ever obtainable, several local factors and
patient’s characteristics should be considered when choosing an
alternative approach. Future extension of TAVI to lower risk
patients will probably result in a relative increase of transfemoral
procedures. Nonetheless, in those higher risk patients in which
the femoral approach is precluded, alternative routes, either
percutaneously or surgically achieved might represent a concrete
opportunity. When willing to avoid either general anesthesia
and/or sternum/rib opening with pulmonary deflation, an
option that could result as a game changer in the post op
management of elderly patients allowing early mobilization
and discharge, the axillary (either surgically or percutaneously
performed) and trans-carotid access can be considered as
a second option. On the other hand, local expertise might
favor trans-aortic or trans-apical approaches due to their wide
availability.
Surely, while no clear indications are still available,
TAVI operators are called to a tailored decision making.
Comprehensive patient’s evaluation as well as extensive
discussion within the heart team will represent the key points to
achieve good procedural and long term outcomes.
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